Reduce risks across extraluminal access points.
3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing is the ONLY transparent dressing cleared by the Food and Drug Administration (FDA) to reduce catheter-related bloodstream infections (CRBSI) and vascular catheter colonization that aligns with evidence-based guidelines and practice standards.
-
*In vitro testing shows that the film provides a barrier against viruses 27 nm in diameter or larger while the dressing remains intact without leakage.
The Food and Drug Administration
Tegaderm™ CHG I.V. Securement Dressing is intended to reduce vascular catheter colonization and catheter-related bloodstream infections (CRBSI) in patients with central venous or arterial catheters. Tegaderm™ CHG I.V. Securement Dressing is the only transparent dressing cleared and proven to reduce CRBSI.¹
The Centers for Disease Control and Prevention
For patients aged 18 years and older: Chlorhexidine-impregnated dressings with an FDA-cleared label that specifies a clinical indication for CRBSI or CABSI are recommended to protect the insertion site of short-term, non-tunneled CVCs. (Category IA)²
Association for Professionals in Infection Control and Epidemiology
If applicable, chlorhexidine-impregnated sponge dressing or chlorhexidine-impregnated dressing can be used. (IB) If a chlorhexidine-sponge dressing is used, [ensure] it is oriented correctly and changed at the same time as the transparent dressing.³
Society for Healthcare Epidemiology of America
Use chlorhexidine-containing dressings for CVCs in patients over 2 months of age. (quality of evidence: I)⁴
Infusion Nurses Society
Use chlorhexidine-impregnated dressings over CVADs to reduce infection risk when extraluminal route is primary source of infection. (Level l) Assess the catheter-skin junction site and surrounding area for redness, tenderness, swelling, drainage by visual inspection and palpation through the intact dressing.⁵
Oncology Nurse Society
Use a CHG-impregnated sponge dressing for all catheters, including specialty catheters in patients older than 2 months of age. Following CHG skin preparation, it is recommended to use a CHG impregnated dressing for any long-term infusion (defined as exceeding 4–6 hours) or if the port remains accessed for intermittent long-term infusions.⁶
All you need. All in one. The only one.
-
Infection Reduction
Cleared and clinically proven to reduce CRBSI. Meets standards and guidelines including CDC Guidelines recommendation for use of chlorhexidine-impregnated dressing with FDA indication to reduce CRBSI.
-
Site Visibility
Transparent dressing and gel pad enable early identification of potential complications at IV site and meet Infusion Nurses Society (INS) recommendation to assess the IV site and surrounding area by visual inspection.⁵
-
Catheter Securement
Designed to minimize catheter movement and dislodgement and meets the INS definition of an Engineered Stabilization Device (ESD)⁵. Tegaderm™ CHG I.V. Securement Dressing 1657 can withstand an average 1.09 lb greater pull force vs. SorbaView® SHIELD + BIOPATCH® 7 days after application.⁷
-
Ease of Use
Integrated CHG gel pad and dressing design ensure standardized, correct application.⁸
Continuous innovation inspired by you.
The clear truth.
-
The difference is clear
Are your patients protected against CRBSI? See the comparison of design and performance of two CHG containing products.
-
The evidence is clear (PDF, 755 KB)
We’re proud to have a robust body of clinical evidence supporting the use of Tegaderm™ CHG Dressing for infection reduction, antimicrobial protection, ease of use and health economics.
-
The value is clear (PDF, 2.23 MB)
All-in-one design is cost effective and eliminates the need to manage, store and distribute multiple products. The integrated design helps ensure compliance and streamlines education and training.
-
3M™ Peak™ Clinical Outcomes Program
The 3M™ Peak™ Clinical Outcomes Program provides you with the resources and partnership you need to define and achieve the outcomes most important to you, your patients and your organization.
-
Access IV product training resources
At 3M, we’re committed to providing ongoing training and support to help you improve clinical outcomes. That’s why we offer resources to help you learn how to use the vascular access products that your facility uses.
-
Stop Bloodstream Infections Before They Start
As your partner in protecting patients, we want to do everything in our power to help you achieve your goal of zero bloodstream infections. Learn more about free educational resources and evidence-based products to help you stop bloodstream infections before they start.
-
Make peripherals a central focus
Learn how to reduce the risk of peripheral IV complications at all access points and make peripherals a central focus of your IV care program.
Explore how science and innovation are transforming the healthcare industry.
Thank You
Thank you for connecting with 3M! We’ll be in touch with you shortly.
Our Apologies...
An error has occurred while submitting. Please try again later...
-
Important Safety Information for 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressings and 3M™ Tegaderm™ CHG Chlorhexidine Gluconate Gel Pad. Do not use Tegaderm™ CHG I.V. Securement Dressings or Tegaderm™ CHG Gel Pad on premature infants or infants younger than two months of age. Use of these products on premature infants may result in hypersensitivity reactions or necrosis of the skin. The safety and effectiveness of Tegaderm™ CHG I.V. Securement Dressings and Tegaderm™ CHG Gel Pad has not been established in children under 18 years of age. For full prescribing information, see the Instructions for Use (IFU). Rx Only.
References
1) U.S. Food and Drug Administration, Department of Health & Human Services. 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing 510(k) K153410 approval letter, May 15, 2017. Retrieved June 18, 2020 from https://www.accessdata.fda.gov/cdrh_docs/pdf15/K153410.pdf (PDF, 161 KB).
2) Centers for Disease Control and Prevention (CDC): O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011;52(9):e162-e193.
3) Association for Professionals in Infection Control and Epidemiology, Inc. APIC Implementation Guide: Guide to Preventing Central Line-Associated Bloodstream Infections, 2015. https://apic.org/Resource_/TinyMceFileManager/2015/APIC_CLABSI_WEB.pdf (PDF, 2.19 MB).
4) Marschall J, Mermel LA, Fakih M, et al. Strategies to Prevent Central Line-Associated Bloodstream Infections in Acute Care between Hospitals: 2014 Update. Infect Control Hosp Epidemiol. 2014;35(7)753-771.
5) Infusion Nurses Society (INS): Gorski L, Hadaway L, Hagle ME, McGoldrick M, Orr M, Doellman D. Infusion Therapy Standards of Practice. J Infus Nurs. 2016;39(suppl 1):S1-S59.
6) Oncology Nursing Society. Access device standards of practice for oncology nursing. 2017. https://www.ons.org/books/access-device-standardspractice-oncology-nursing.
7) 3M data on file. EM-05-014359.
8) Kohan CA, Boyce JM. A Different Experience with Two Different Chlorhexidine Gluconate Dressings for Use on Central Venous Devices. Am J Infect Control. 2013;41(6):S142–S143.